Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc is advancing its gene therapy, cellular regeneration, and precision medicine platforms, with promising initial data from its Phase 1b study of TN-201, indicating positive trends in clinical parameters and cardiac biomarkers. The company reported fourth-quarter earnings per share (EPS) of ($0.28) for 2024, which aligns closely with estimates and demonstrates tighter financial performance relative to previous expectations. Additionally, the potential for TN-201 in addressing MYBPC3-associated hypertrophic cardiomyopathy (HCM) and the management of liver enzyme elevations suggest a favorable environment for future product development and market positioning.

Bears say

Tenaya Therapeutics Inc faces a negative outlook primarily due to potential delays in transitioning its preclinical assets to clinical trials, which could weaken market sentiment and necessitate downward revisions to financial estimates. Additionally, the complexity and novelty of AAV-based gene therapy products pose significant risks related to manufacturing capacity, potentially leading to further setbacks in product development and commercialization. Compounded by the possibility of failed clinical trials and reliance on dilutive capital raises to secure funding, these fundamental challenges create uncertainties that may materially constrain Tenaya’s financial forecasts.

Tenaya Therapeutic (TNYA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Buy based on their latest research and market trends.

According to 6 analysts, Tenaya Therapeutic (TNYA) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.